TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01470248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide
Description: Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
Study: NCT03137238

Intervention type: OTHER
Intervention: Investigation of self-perception in Parkinson's disease
Description: There is no therapeutic intervention.

Intervention type: OTHER
Intervention: Investigation of self-perception in Parkinson's disease
Description: There is no therapeutic intervention.

Intervention type: OTHER
Intervention: Investigation of self-perception in Parkinson's disease
Description: There is no therapeutic intervention.

Intervention type: OTHER
Intervention: Investigation of self-perception in Parkinson's disease
Description: There is no therapeutic intervention.
Study: NCT01553422

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy (Saline Normal)
Description: Saline Normal 1 Lit. during 30 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluid therapy (Saline Normal)
Description: saline Normal 1 lit during 30 minutes
Study: NCT02215369

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VenaCure EVLT 400 µm fiber Procedure Kit
Description: The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
Study: NCT04297748

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 89Zirconium-M7824
Description: PET imaging agent

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 89Zirconium-M7824
Description: PET imaging agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Bifunctional fusion protein intended to block PD-L1 and neutralize TGFbeta simultaneously.
Study: NCT00457197

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active medication in appearance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
Study: NCT00605631

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System
Description: No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System
Description: No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.

Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System
Description: No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
Study: NCT01549587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.243% sodium fluoride
Description: dentifrice: brush thoroughly twice daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: toothbrush
Description: brush thoroughly twice daily

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental floss
Description: floss the whole mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride
Description: dentifrice: twice daily brush thoroughly for 2 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: toothbrush
Description: twice daily brush thoroughly for 2 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.07% Cetylpyridinium chloride
Description: mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental floss
Description: floss the whole mouth once daily
Study: NCT02678065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InPact Admiral DEB
Study: NCT01195012

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Helping HAND (Healthy Nutrition and Activity Directions)
Description: 6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
Study: NCT02224729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT01362140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: Administered by subcutaneous injection every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection every 3 weeks
Study: NCT02774057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captafer®
Description: 2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Captafer®
Description: 2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems
Study: NCT00034281

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-165
Description: Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
Study: NCT01508091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: energy restricted mediterranean-type diet
Description: Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 25 % calorie restriction
Description: 25 % calorie restriction respect total energy expenditure
Study: NCT01068678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
Study: NCT03314792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol
Description: * Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.~* Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: * OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.~* OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded.
Study: NCT04033861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBNP
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
Study: NCT00328211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)
Description: 15 mg/kg/day for 18 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)
Description: 15 mg/kg/day for 18 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sphingomyelin
Description: 1000mg/day for 19 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: C13 Stable isotope of Cholesterol
Description: Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
Study: NCT01965366

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality exposure therapy
Description: Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Virtual reality exposure therapy
Description: Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg DEX
Description: A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
Study: NCT01208974

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple-Sparing Mastectomy
Description: Subcutaneous Mastectomy (SCM) to be performed, preserving the nipple and areola complex, after a frozen section of the tissue underneath the nipple-areola complex is sampled and found to be negative for tumor. Performed during Week 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction
Description: Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire. Performed during Week 1.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary Surgery
Description: Axillary Dissection or Sentinel Node Biopsy (SNB) will be performed at surgeon's discretion.
Study: NCT02774057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Sulfate
Description: 195 mg Iron supplement
Study: NCT01208974

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Nipple-Areolar Complex RT
Description: Prophylactic Nipple-Areolar Complex Radiation Therapy per protocol. Administered between weeks 5 to 8.
Study: NCT03669926

Intervention type: RADIATION
Group type: OTHER
Intervention: Digital Breast Tomosynthesis+synthetic mammography
Description: Two-view tomosynthesis performed with GE Senographe Pristina.
Study: NCT02673931

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Byetta (Lilly, Exenatide)
Description: See description of arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conoxia (AGA, oxygen)
Description: See description arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conoxia (AGA, oxygen)
Description: See description arms

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 20% Human Albumin
Study: NCT03722563

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total laparoscopic hysterectomy with sacrocolpopexy
Description: Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total laparoscopic hysterectomy with lateral suspension
Description: Surgical correction of anterior and/or apical pelvic organ prolapse by laparoscopy
Study: NCT01915134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Endostatin plus gemcitabine and cisplatin
Description: target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and cisplatin
Description: only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
Study: NCT01703364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs~Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days~Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days
Study: NCT00540280

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin
Description: Surgery + Chemo + RT
Study: NCT04423068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SexHealth II
Description: SexHealth II is an intervention that will focus exclusively on provision of hormonal contraception counseling and provision for hospitalized female adolescents

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Contraceptive
Description: The investigators will offer initiation of the following contraceptives:~Ethinyl Estradiol and Etonogestrel 0.015mg-0.12mg vaginal ring (Nuva Ring) Etonogestrel 68mg subcutaneous implant (Nexplanon) Medroxyprogesterone 150mg/ml 150 mg IM injection Ethinyl Estradiol and Norgestimate (Sprintec) 35mcg-0.25mg tablet Norelgestromin/Ethinyl estradiol transdermal patch (Ortho Evra) Norethindrone 0.35mg tablet~Emergency Contraception:~Ulipristal 30 mg tablet Levonorgestrel 1.5mg tablet
Study: NCT02486328

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Dosage adjustment

Intervention type: DRUG
Group type: OTHER
Intervention: Meperidine
Description: Dosage adjustment

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: Dosage adjustment

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Dosage adjustment
Study: NCT01143948

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine & Glulisine
Description: Basal Glargine \& bolus Glulisine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular insulin
Description: Sliding scale regular insulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPH & regular insulin
Description: Basal NPH \& bolus regular insulin
Study: NCT01754831

Intervention type: DEVICE
Group type: OTHER
Intervention: Fluoride varnish
Description: Topical application of fluoride varnish on present teeth
Study: NCT03341390

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 1 x 325 mg tablet of aspirin administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 1 x 325 mg tablet of aspirin administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: 1 x 325 mg tablet of aspirin administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Description: 200 mg of BMS-986177 administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200 mg of Placebo administered twice daily
Study: NCT00386360

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: oral weekly for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risedronate
Description: 35 mg risedronate, once a week for one year
Study: NCT02594982

Intervention type: OTHER
Group type: OTHER
Intervention: intervention bundle (sedation, pain, mobilization and sleep)
Description: Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.~Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night
Study: NCT04016389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is an antineoplastic agent that is commonly used for the treatment of cervical cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel is an antineoplastic agent that is commonly used in combination with cisplatin or carboplatin for the treatment of cervical cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trachelectomy
Description: Surgery to remove the cervix but keep the uterus intact.
Study: NCT05651048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BEMER Group
Description: BEMER therapy and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
Study: NCT03061253

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Cigarette and behavioural change support.
Description: The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nicotine-Free Electronic Cigarette and behavioural change support.
Description: Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
Study: NCT04188925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture
Description: The LA is using a gallium aluminum arsenide LaserPen (maximal power, 150 mW; wavelength, 810nm; area of probe, 0.03cm2; power density, 5W/cm2; pulsed wave; RJ-Laser, Reimers \& Janssen GmbH, Waldkirch, Germany). The LA treatment will be applied to EX-LE5, ST35, and BL40 for 80 seconds, under power 150mW, to deliver a total treatment dose of 6 Joule/ cm2.~The EA is the combination of acupuncture and transcutaneous electrical nerve stimulator. The transcutaneous electrical nerve stimulator is produced by Ching Ming Medical Device Company. This machine is verified by Department of Health in Taiwan, with the ID number 001147. We perform acupuncture on GB33, GB34, SP9, SP10, and ST36.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Laser Acupuncture
Description: Sham LA is using the same appearance of LaserPen without energy output to perform the same acupoint as above description. Both of the LaserPen in two groups are labeled with A and B, one of them is revised by the company to become the sham LA. The outward of both LaserPen are the same and our physician does not know which one is the real.
Study: NCT05651048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape Group
Description: Kinesiotape application and Physiotherapy and Rehabilitation Program After Videothoracoscopy Surgery
Study: NCT00183859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: Intraperitoneal Irinotecan given every three weeks
Study: NCT03061253

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy and behavioural change support.
Description: Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
Study: NCT00790374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BN83495 (Cohort 1)
Description: 20 mg daily BN83495 for 28 days